UPCC 10519 / I5B-MC-Y001: An Open-Label Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma
Enrolling By Invitation
99 years or below
All
2 participants needed
1 Location
Brief description of study
The purpose of this program is to allow patients who, in consultation with their treating physician, feel it is in their best interest to continue to receive olaratumab. Only patients with soft tissue sarcoma who are already being treated with olaratumab may enter this program.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: oncology, sarcoma
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 834053
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
